Administrative Core

行政核心

基本信息

项目摘要

ADMINISTRATIVE CORE Abstract The administrative core will lead, manage, and support all activities of the Acquired Resistance to Therapy Network (ARTNet) Center for Pancreatic Cancer (ACPC). It will represent ACPC at the trans-ARTNet network activities, and in interactions with NCI. The ARTNet administrative core will be responsible for managing the activities of the synergistic research ACPC projects with scientific and technical expertise and resources in the areas of therapy resistance, signaling, metabolism, pancreatic cancer biology, organoid and mouse models, immune and non-immune stroma, and PDAC tissues for studying the acquired therapy resistance in cancer. The core leadership will provide expertise spanning the basic to translational spectrum, consistent with the overarching theme of ACPC, with track records of building and guiding large scientific teams to successfully advance fields in transformative ways. We will utilize strategic management with innovative approaches, including an educational component to bring new talent into the field, engage diverse teams to facilitate new ideas, leverage national talent pertinent to the proposed goals, engage university leadership in building support for cutting-edge science, and utilize dedicated university expertise to facilitate engagement with basic and translational research programs to grow ARTNet centric interests. The administrative core will provide support for personnel involved in the administration, coordination, communication, biostatistics, and bioinformatics to support the ARTNet activities within the center and campus, other ARTNet centers, ARTNet Coordinating Data and Management Center (CDMC) and National Cancer Institutes (NCI). The administrative core will also provide scientific oversight, result dissemination, budgetary oversight, and clerical functions associated with the overall research program in this ACPC application. The core will implement center-wide activities which include, developing new collaborations on the ACPC projects, organize annual retreat, support acquired cancer therapy resistance seminar speakers within various academic units, advocate for the next generation of scientists (graduate students, postdoctoral researchers, and junior faculty) in the ACPC member laboratories. Finally, the administrative core will represent ACPC on the ARTNet steering committee.
行政核心 抽象的 行政核心将领导,管理和支持所获得的治疗抵抗的所有活动 网络(ARTNET)胰腺癌中心(ACPC)。它将代表trans-artnet网络上的ACPC 活动,以及与NCI的互动。 ARTNET行政核心将负责管理 具有科学和技术专业知识和资源的协同研究ACPC项目的活动 治疗耐药性,信号传导,代谢,胰腺癌生物学,类器官和小鼠模型的领域, 免疫和非免疫基质和PDAC组织用于研究癌症中获得的治疗耐药性。这 核心领导将提供跨越基础转化范围的专业知识,与 ACPC的总体主题,并有建筑物的记录和指导大型科学团队成功 以变​​革性的方式提前领域。我们将采用创新方法利用战略管理, 包括一个教育组成部分,将新人才带入领域,让多元化的团队促进新的新人才 想法,利用与拟议目标有关的国家人才,使大学领导参与建立支持 用于尖端的科学,并利用专门的大学专业知识来促进与基本和基础的参与 转化研究计划,以增加以ARTNET为中心的利益。行政核心将提供支持 对于参与行政,协调,沟通,生物统计学和生物信息学的人员 支持中心和校园内的ARTNET活动,其他Artnet中心,ARTNET协调数据 和管理中心(CDMC)和国家癌症研究所(NCI)。行政核心也将提供 科学监督,结果传播,预算监督和与整体相关的文书功能 此ACPC应用程序中的研究计划。核心将实施包括,包括, 在ACPC项目上开发新的合作,组织年度务虚会,支持获得的癌症治疗 电阻研讨会的演讲者在各个学术单位中,倡导下一代科学家 (研究生,博士后研究人员和初级教师)在ACPC成员实验室中。最后, 行政核心将代表ACPC参加ARTNET指导委员会。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Pankaj Kumar Singh其他文献

In silico guided development of imine-based inhibitors for resistance-deriving kinases
计算机引导开发基于亚胺的耐药激酶抑制剂
Utilization of wastewater as nutrient media and biomass valorization in marine Chrysophytes- Chaetoceros and Isochrysis
废水作为营养介质的利用和海洋金藻植物-角毛藻和等鞭金藻的生物量增值
  • DOI:
    10.1016/j.ecmx.2020.100062
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Pankaj Kumar Singh;Raya Bhattacharjya;A. Saxena;Bharti Mishra;A. Tiwari
  • 通讯作者:
    A. Tiwari
Biomass valorization of agriculture wastewater grown freshwater diatom Nitzschia sp. for metabolites, antibacterial activity, and biofertilizer.
农业废水的生物质增值淡水硅藻菱形藻。
  • DOI:
    10.1016/j.biortech.2023.128976
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    11.4
  • 作者:
    Pankaj Kumar Singh;A. Saxena;Rashi Tyagi;R. Sindhu;P. Binod;A. Tiwari
  • 通讯作者:
    A. Tiwari
A multifaceted approach towards valorizing diatom Thalassiosira weissflogii, cultivated on diluted municipal wastewater for enhanced biodiesel production
一种多方面的方法来评估硅藻 Thalassiosira weissflogii 的价值,该硅藻是在稀释的城市废水中培养的,以提高生物柴油的产量
  • DOI:
    10.1016/j.fuel.2022.125311
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    7.4
  • 作者:
    Pankaj Kumar Singh;Raya Bhattacharjya;Bharti Mishra;A. Saxena;A. Tiwari
  • 通讯作者:
    A. Tiwari
Traditional, Current and Prospective Therapeutic Uses of Muntingia calabura: A Comprehensive Literature Review
Muntingia calabura 的传统、当前和未来治疗用途:综合文献综述
  • DOI:
    10.3923/rjmp.2023.09.22
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Bhanita Saud;K. M. Geetha;Sonal Dubey;Pankaj Kumar Singh;Shweta Shrivastava;Dilpreet Singh;Prashant Tiwari
  • 通讯作者:
    Prashant Tiwari

Pankaj Kumar Singh的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Pankaj Kumar Singh', 18)}}的其他基金

Metabolic regulation of FOLFIRINOX acquired resistance in pancreatic cancer
FOLFIRINOX 在胰腺癌中获得性耐药的代谢调节
  • 批准号:
    10518247
  • 财政年份:
    2022
  • 资助金额:
    $ 30.72万
  • 项目类别:
Pancreatic Cancer ARTNet Center
胰腺癌 ARTNet 中心
  • 批准号:
    10707504
  • 财政年份:
    2022
  • 资助金额:
    $ 30.72万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10518244
  • 财政年份:
    2022
  • 资助金额:
    $ 30.72万
  • 项目类别:
Cancer Metabolism Core
癌症代谢核心
  • 批准号:
    10707540
  • 财政年份:
    2022
  • 资助金额:
    $ 30.72万
  • 项目类别:
Pancreatic Cancer ARTNet Center
胰腺癌 ARTNet 中心
  • 批准号:
    10518243
  • 财政年份:
    2022
  • 资助金额:
    $ 30.72万
  • 项目类别:
Cancer Metabolism Core
癌症代谢核心
  • 批准号:
    10518246
  • 财政年份:
    2022
  • 资助金额:
    $ 30.72万
  • 项目类别:
Metabolic regulation of FOLFIRINOX acquired resistance in pancreatic cancer
FOLFIRINOX 在胰腺癌中获得性耐药的代谢调节
  • 批准号:
    10707541
  • 财政年份:
    2022
  • 资助金额:
    $ 30.72万
  • 项目类别:
Molecular Basis of ME2-mediated Tumor Suppression in Pancreatic Cancer
ME2 介导的胰腺癌肿瘤抑制的分子基础
  • 批准号:
    10671029
  • 财政年份:
    2022
  • 资助金额:
    $ 30.72万
  • 项目类别:
Mitochondrial calcium signaling in pancreatic cancer metastasis and progression
胰腺癌转移和进展中的线粒体钙信号传导
  • 批准号:
    10363987
  • 财政年份:
    2022
  • 资助金额:
    $ 30.72万
  • 项目类别:
Mitochondrial calcium signaling in pancreatic cancer metastasis and progression
胰腺癌转移和进展中的线粒体钙信号传导
  • 批准号:
    10565949
  • 财政年份:
    2022
  • 资助金额:
    $ 30.72万
  • 项目类别:

相似海外基金

Applied Systems Biology Core
应用系统生物学核心
  • 批准号:
    10746901
  • 财政年份:
    2023
  • 资助金额:
    $ 30.72万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10716153
  • 财政年份:
    2023
  • 资助金额:
    $ 30.72万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10749843
  • 财政年份:
    2023
  • 资助金额:
    $ 30.72万
  • 项目类别:
Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas
通过合作进行治愈:利用合作团体对抗慢性淋巴细胞白血病和 B 细胞淋巴瘤
  • 批准号:
    10566833
  • 财政年份:
    2023
  • 资助金额:
    $ 30.72万
  • 项目类别:
Optimizing Supportive Care for Patients with Metastatic Lung Cancer in the Era of Precision Oncology
在精准肿瘤学时代优化转移性肺癌患者的支持护理
  • 批准号:
    10448560
  • 财政年份:
    2022
  • 资助金额:
    $ 30.72万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了